Advertisement

Breast Cancer Research and Treatment

, Volume 168, Issue 2, pp 481–482 | Cite as

Correction to: Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors

  • Sarah J. O. Nomura
  • Yi-Ting Hwang
  • Scarlett Lin Gomez
  • Teresa T. Fung
  • Shu-Lan Yeh
  • Chiranjeev Dash
  • Laura Allen
  • Serena Philips
  • Leena Hilakivi-Clarke
  • Yun-Ling Zheng
  • Judy Huei-yu Wang
Correction
  • 616 Downloads

Correction to: Breast Cancer Research and Treatment  https://doi.org/10.1007/s10549-017-4578-9

In the original publication, the values provided for the isoflavone and glucosinolate intake variables were incorrectly labeled in Table 1. The correct values of 6.3 mg/day for isoflavone intake, and 20.4 mg/day and 50.1 mg/day for glucosinolate intake are provided in this erratum. Under the “Statistical Analysis” section, second paragraph, the values in the 11th line “…time since diagnosis (< 4, 3–36, and ≥ 36 months)…” was mislabeled. The correct values were “< 24, 24–36, and > 36 months”.
Table 1

Population characteristics

 

Total population

Non-Hispanic White

Chinese American

Total N (%)

365 (100)

173 (47.4)

192 (52.6)

Age in years (mean, SD)

57.1 (10.4)

57.2 (10.5)

56.9 (10.4)

Menopausal status (N, %)

 Premenopause

47 (13.0)

21 (12.3)

26 (13.7)

 Induced menopause

61 (16.9)

30 (17.5)

31 (16.3)

 Perimenopause

81 (22.4)

35 (20.5)

46 (24.2)

 Postmenopause

172 (47.6)

85 (49.7)

87 (45.8)

BMI (kg/m2) (mean, SD)

24.0 (4.4)

25.2 (5.1)

22.9 (3.1)

Physical activity (N, %)a

 Active

110 (30.1)

77 (44.5)

33 (17.2)

 Minimally active

136 (37.3)

58 (33.5)

78 (40.6)

 Inactive

119 (32.6)

38 (22.0)

81 (42.2)

Cancer stage (N, %)

 Stage 0

110 (30.1)

64 (37.0)

46 (24.0)

 Stage I

166 (45.4)

77 (44.5)

89 (46.4)

 Stage II

47 (12.9)

22 (12.7)

25 (13.0)

 Stage III

42 (11.5)

10 (5.8)

32 (16.7)

Endocrine therapy (N, %)

 None

148 (40.8)

74 (42.8)

74 (38.5)

 Tamoxifen

126 (34.5)

60 (34.7)

66 (34.4)

 Aromatase inhibitor

91 (24.9)

39 (22.5)

52 (27.1)

Lumpectomy (N, %)

 No

141 (38.6)

59 (34.1)

82 (42.5)

 Yes

224 (61.4)

114 (65.9)

110 (57.3)

Mastectomy (N, %)

 No

228 (62.5)

114 (65.9)

114 (59.4)

 Yes

137 (37.5)

59 (34.1)

78 (40.6)

Chemotherapy (N, %)

 No

257 (76.3)

127 (80.4)

130 (72.6)

 Yes

80 (23.7)

31 (19.6)

49 (27.4)

Radiation therapy (N, %)

 No

198 (54.2)

88 (50.9)

110 (57.3)

 Yes

167 (45.8)

85 (49.1)

82 (42.7)

Time since diagnosis (N, %)

 < 24 months

108 (29.6)

48 (27.7)

60 (31.3)

 24–36 months

111 (30.4)

49 (28.3)

62 (32.3)

 > 36 months

146 (40.0)

76 (43.9)

70 (36.5)

Estrogen receptor (N, %)

 Positive

227 (62.2)

109 (63.0)

118 (61.5)

 Negative

49 (13.4)

19 (11.0)

30 (15.6)

 Unknown

89 (24.4)

45 (26.0)

44 (22.9)

Progesterone receptor (N, %)

 Positive

196 (53.7)

91 (52.6)

105 (54.7)

 Negative

80 (21.9)

37 (21.4)

43 (22.4)

 Unknown

89 (24.4)

45 (26.0)

44 (22.9)

HER2 (N, %)

 Positive

44 (12.1)

18 (10.4)

26 (13.5)

 Negative

167 (45.8)

74 (42.8)

93 (48.4)

 Unknown

154 (42.2)

81 (46.8)

73 (38.0)

Soy products (N, %)b

 No intake

104 (28.5)

73 (42.2)

31 (16.1)

 > 0–< 24.0 g/day

131 (35.9)

65 (37.6)

66 (34.4)

 ≥ 24.0 g/day

130 (35.6)

35 (20.2)

95 (49.5)

Isoflavones (N, %)b

 No intake

104 (28.5)

73 (42.2)

31 (16.1)

 >0–< 6.3 mg/day

129 (35.3)

62 (35.8)

67 (34.9)

 ≥ 6.3 mg/day

132 (36.2)

38 (22.0)

94 (49.0)

Cruciferous vegetables (N, %)b

 < 33.0 g/day

121 (33.2)

77 (44.5)

44 (22.9)

 ≥ 33.0–< 70.8 g/day

120 (32.9)

58 (33.5)

62 (32.3)

 ≥ 70.8 g/day

124 (33.9)

38 (22.0)

86 (44.8)

Glucosinolates (N, %)b

 ≤ 20.4 mg/day

121 (33.2)

70 (40.5)

51 (26.6)

 > 20.4–< 50.1 mg/day

120 (32.9)

55 (31.8)

65 (33.9)

 ≥ 50.1 mg/day

124 (33.9)

48 (27.7)

76 (39.6)

aActive: vigorous physical activity ≥ 3 days/week + ≥ 1500 MET-minutes/week or ≥ 3000 MET-minutes/week engaged in any intensity levels of physical activity; minimally active: < Active cut-points and ≥ 600 MET-minutes/week; inactive: < 600 MET-minutes/week

bTertiles

The authors wish to clarify the description of a prior study by Dorjgochoo et al. (2011) in the discussion section: “an observational study among Chinese survivors found that higher soy food intake (45–47 mg/day) increased hot flashes at 6 or 36 months post-breast cancer diagnosis [16]”. The phrase “higher soy food intake (45–47 mg/day)” should have been “higher soy isoflavone intake (> 62.86 mg/day)”. The Dorjgochoo et al. study was referring to soy isoflavone intake specifically and 45–47 mg/day actually refers to the average daily intake of soy isoflavone. Additionally, the authors stated that the Dorjgochoo et al. study “only assessed hot flashes as menopausal symptom outcome”. It should be clarified that the Dorjgochoo et al. study assessed multiple menopausal symptoms but the current study assessed more.

The clarifications mentioned in this erratum do not influence or modify the results and conclusions reported in the original article.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Sarah J. O. Nomura
    • 1
  • Yi-Ting Hwang
    • 2
  • Scarlett Lin Gomez
    • 3
  • Teresa T. Fung
    • 4
    • 5
  • Shu-Lan Yeh
    • 6
  • Chiranjeev Dash
    • 1
  • Laura Allen
    • 3
  • Serena Philips
    • 7
  • Leena Hilakivi-Clarke
    • 1
  • Yun-Ling Zheng
    • 1
  • Judy Huei-yu Wang
    • 1
    • 8
  1. 1.Department of Oncology, Lombardi Comprehensive Cancer CenterGeorgetown UniversityWashington, D.C.USA
  2. 2.Department of StatisticsNational Taipei UniversityTaipeiTaiwan
  3. 3.Cancer Prevention Institute of CaliforniaFremontUSA
  4. 4.Department of NutritionSimmons CollegeBostonUSA
  5. 5.Department of NutritionHarvard T. H. Chan School of Public HealthBostonUSA
  6. 6.Department of NutritionChang Shan Medical UniversityTaichungTaiwan
  7. 7.Milken Institute School of Public HealthGeorge Washington UniversityWashington, D.C.USA
  8. 8.Washington, D.C.USA

Personalised recommendations